+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 3Months - 70Years
All Genders
ID02638389

Phase III Study of Sirolimus for Treating Complex Vascular Malformations Not Responding to Standard Care

Led by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Updated on 2023-02-24

250

Participants Needed

3

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effectiveness and safety of Rapamycin sirolimus, an mTor inhibitor, in people with complex vascular malformations that do not respond well to standard treatments like surgery or sclerotherapy. These malformations can cause chronic pain and serious health issues. This phase III multicenter study aims to provide better treatment guidelines by enrolling about 250 patients, including both children and adults. Participants with venous, lymphatic, or complex vascular malformations will receive sirolimus. The study evaluates sirolimus given as a drug to see if it improves the condition and is safe to use. This study includes ongoing treatment and monitoring over a period of up to two years. During the study, participants will regularly assess their symptoms and quality of life using a visual scale every three months. Researchers will also monitor any side effects monthly at first, then every three months. Imaging tests like MRI will measure changes in the malformations after 12 months. Digital photographs and other evaluations will help track treatment effects over the two-year period.

CONDITIONS

Brief Title

Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

Research Team

L

Laurence M. Boon, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here